10x Genomics Inc [TXG] stock is trading at $19.55, up 7.83%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The TXG shares have lost -0.66% over the last week, with a monthly amount glided 24.44%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
10x Genomics Inc [NASDAQ: TXG] stock has seen the most recent analyst activity on July 22, 2024, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $24 for it. Previously, JP Morgan downgraded its rating to Neutral on July 18, 2024, and dropped its price target to $20. On July 10, 2024, downgrade downgraded it’s rating to Hold and revised its price target to $25 on the stock. Wolfe Research downgraded its rating to a Peer Perform. Guggenheim downgraded its rating to a Neutral. In a note dated May 01, 2024, TD Cowen downgraded an Hold rating on this stock and revised its target price from $57 to $32.
10x Genomics Inc [TXG] stock has fluctuated between $15.28 and $57.90 over the past year. Currently, Wall Street analysts expect the stock to reach $26.25 within the next 12 months. 10x Genomics Inc [NASDAQ: TXG] shares were valued at $19.55 at the most recent close of the market. An investor can expect a potential return of 34.27% based on the average TXG price forecast.
Analyzing the TXG fundamentals
10x Genomics Inc [NASDAQ:TXG] reported sales of 625.45M for the trailing twelve months, which represents a growth of 5.01%. Gross Profit Margin for this corporation currently stands at 0.64% with Operating Profit Margin at -0.37%, Pretax Profit Margin comes in at -0.37%, and Net Profit Margin reading is -0.38%. To continue investigating profitability, this company’s Return on Assets is posted at -0.26, Equity is -0.33 and Total Capital is -0.28. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.12.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 18.58 points at the first support level, and at 17.61 for the second support level. However, for the 1st resistance point, the stock is sitting at 20.06, and for the 2nd resistance point, it is at 20.57.
Ratios To Look Out For
For context, 10x Genomics Inc’s Current Ratio is 5.22. In addition, the Quick Ratio stands at 4.45 and the Cash Ratio stands at 3.42. Considering the valuation of this stock, the price to sales ratio is 3.74, the price to book ratio is 3.26.
Transactions by insiders
Recent insider trading involved Saxonov Serge, Chief Executive Officer, that happened on May 22 ’24 when 4877.0 shares were sold., Hindson Benjamin J. completed a deal on May 22 ’24 to sell 4087.0 shares. Meanwhile, Chief Financial Officer McAnear Justin J. sold 2936.0 shares on May 22 ’24.
